Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
2018 · New England Journal of Medicine · 2,100 citations
https://doi.org/10.1056/nejmoa1716078
J
Jiajia Zhang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
127
Papers
5.4K
Citations
25
h-index
43
i10-index
Jiajia Zhang is an academic researcher from Shihezi University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 25, co-authored 108 publications.
ORCID: 0000-0003-4623-6134Papers by this author
worksTranscriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
2021 · Nature · 519 citations
https://doi.org/10.1038/s41586-021-03752-4
Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
2022 · Cell Death Discovery · 64 citations
https://doi.org/10.1038/s41420-022-01256-2
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
2022 · The Journal of Experimental Medicine · 45 citations
https://doi.org/10.1084/jem.20212169
Myeloid-Derived Growth Factor Promotes Intestinal Glucagon-Like Peptide-1 Production in Male Mice With Type 2 Diabetes
2020 · Endocrinology · 30 citations
https://doi.org/10.1210/endocr/bqaa003
A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
2021 · Clinical Epigenetics · 28 citations
https://doi.org/10.1186/s13148-021-01014-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat